EF Hutton analyst Michael King initiated coverage of Sonnet BioTherapeutics with a Buy rating and $6.70 price target. Sonnet is a small-cap biotech company utilizing sophisticated protein engineering to maximize the benefits of timeless cytokines, King tells investors in a research note. The analyst says the company "leverages the many protein players mixing it up in the tumor microenvironment."
Published first on TheFly
